SCHEMBL15464909

SCHEMBL15464909

COCCNc1nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c2n1Cc1ccccn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 20/20 1.00
▸ CYP3A4 P08684 7/20 1.00
▸ CYP2C9 P11712 6/20 1.00
▸ BRD2 P25440 4/20 0.63
▸ BRD3 Q15059 4/20 0.63
▸ BRDT Q58F21 2/20 0.52
▸ CACNA1A O00555 1/20 0.49
▸ CHRNA1 P02708 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CCL2 P13500 1/20 0.49
▸ KCNA5 P22460 1/20 0.49
▸ TACR1 P25103 1/20 0.49
▸ MAOB P27338 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ AVPR1A P37288 1/20 0.49
▸ PDE4B Q07343 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ SCN5A Q14524 1/20 0.49
▸ CREBBP Q92793 1/20 0.49
▸ KCNH3 Q9ULD8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1903218 0.85 BRD4 (1.00) BRD4CYP3A4CYP2C9BRD2BRD3
SCHEMBL13731816 0.85 BRD4 (1.00) BRD4CYP3A4CYP2C9BRD2BRD3
SCHEMBL15464348 0.84 BRD4 (1.00) BRD4CYP3A4CYP2C9BRD2BRD3
SCHEMBL18308425 0.83 BRD4 (0.80) BRD4CYP3A4CYP2C9BRD2BRD3
SCHEMBL18904313 0.82 BRD4 (0.70) BRD4CYP3A4CYP2C9BRD2BRD3
SCHEMBL15287640 0.81 BRD4 (0.74) BRD4CYP3A4CYP2C9
SCHEMBL1905500 0.81 BRD4 (1.00) BRD4CYP3A4CYP2C9BRD2BRD3
SCHEMBL15288947 0.80 BRD4 (0.78) BRD4CYP3A4CYP2C9BRD2BRD3
SCHEMBL12098660 0.79 BRD4 (0.73) BRD4CYP3A4CYP2C9BRD2BRD3
SCHEMBL16118551 0.78 BRD4 (0.73) BRD4CYP3A4CYP2C9BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699573-B1 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES GLAXOSMITHKLINE LLC (US) 2017-05-31 — — EP claimed
US-8846709-B2 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives GLAXOSMITHKLINE LLC (US) 2014-09-30 — — US claimed
US-20140045834-A1 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives GLAXOSMITHKLINE LLC (US) 2014-02-13 — — US claimed
EP-2699573-B1 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES GLAXOSMITHKLINE LLC (US) 2017-05-31 — — EP disclosed
EP-2699573-B1 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES GLAXOSMITHKLINE LLC (US) 2017-05-31 — — EP disclosed
US-20150133434-A1 Compositions and Methods for Reactivating Latent Immunodeficiency Virus THE J. DAVID GLADSTONE INSTITUTES 2015-05-14 — — US disclosed
US-8846709-B2 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives GLAXOSMITHKLINE LLC (US) 2014-09-30 — — US disclosed
US-8846709-B2 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives GLAXOSMITHKLINE LLC (US) 2014-09-30 — — US disclosed
US-8846709-B2 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives GLAXOSMITHKLINE LLC (US) 2014-09-30 — — US disclosed
US-20140045834-A1 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives GLAXOSMITHKLINE LLC (US) 2014-02-13 — — US disclosed
US-20140045834-A1 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives GLAXOSMITHKLINE LLC (US) 2014-02-13 — — US disclosed
US-20140045834-A1 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives GLAXOSMITHKLINE LLC (US) 2014-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045834-A1 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT2B7, UGT1A7 BRD4 5/4885CYP3A4 45/4885CYP2C9 1133/4885
US-20150133434-A1 Compositions and Methods for Reactivating Latent Immunodeficiency Virus BRD1, BRD3, BRD2 BRD4 9/4885CYP3A4 3690/4885CYP2C9 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback